William Blair Issues Optimistic Estimate for SLN Earnings

Silence Therapeutics plc (NASDAQ:SLN - Free Report) - William Blair boosted their FY2027 EPS estimates for shares of Silence Therapeutics in a research note issued to investors on Thursday, May 8th. William Blair analyst M. Minter now forecasts that the company will earn $13.66 per share for the year, up from their previous estimate of $13.57. The consensus estimate for Silence Therapeutics' current full-year earnings is ($1.77) per share. William Blair also issued estimates for Silence Therapeutics' FY2028 earnings at $24.35 EPS.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%.

SLN has been the subject of several other reports. HC Wainwright reissued a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. Morgan Stanley decreased their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. BMO Capital Markets decreased their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. Chardan Capital decreased their target price on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, The Goldman Sachs Group decreased their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating for the company in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Silence Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $33.83.

Silence Therapeutics Stock Up 9.0%

SLN stock traded up $0.36 during trading hours on Monday, hitting $4.37. The company's stock had a trading volume of 281,395 shares, compared to its average volume of 300,867. The company has a market capitalization of $130.79 million, a PE ratio of -2.78 and a beta of 1.20. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $24.38. The stock has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $6.01.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SLN. JPMorgan Chase & Co. acquired a new position in Silence Therapeutics in the 4th quarter valued at $26,000. GAMMA Investing LLC grew its stake in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after buying an additional 5,233 shares during the last quarter. Barclays PLC grew its stake in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after buying an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Silence Therapeutics in the 4th quarter valued at $69,000. Finally, Virtus ETF Advisers LLC boosted its holdings in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after purchasing an additional 6,098 shares during the period. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.